Navigation Links
Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner
Date:7/22/2009

WATERTOWN, Mass., July 22 /PRNewswire-USNewswire/ -- Biomodels LLC, a pre-clinical research organization best known for its expertise in oral mucositis, today announced it will further increase its work in the areas of cancer supportive care, pulmonary fibrosis, and biphosphonate-related osteoncrosis, with the promotion of Stephen T. Sonis DMD, DMSc to partner.

Dr. Sonis, a world-renowned expert in the clinical treatment and research of cancer regimen-related mucosal toxicities, said the company's collaborative work with pharmaceutical and biotechnology clients in the area of cancer supportive care is expected to grow sharply this year.

"The side effects of cancer treatment are becoming increasing important, as pharmaceutical and biotechnology companies realize that more effective dosing regimens can be achieved if side effects are considered and ameliorated at the pre-clinical stage," Dr. Sonis said.

Biomodels (www.biomodels.com) researchers have identified common mechanisms underlying toxicities that can lead to more rapid pharmaceutical interventions.

"Few people have the opportunity to help take a molecule from inception to patients, especially patients with great clinical need," Dr. Sonis said. "Biomodels' success in assisting industry to make the transition from test tube to the clinic as smoothly, quickly, safely and predictably as possible has been exciting for me.

"I look forward to our continued development of innovative models that expedite the clinical development process, especially to meet the challenges posed by regimen-related toxicities of cancer therapy," he added.

Biomodels is internationally known for its work in developing predictive animal models that are helping to determine which patients are predisposed to mucositis, osteonecrosis, cancer treatment-related thrombosis, gastrointestinal toxicity, pulmonary fibrosis, and salivary gland changes.

Dr. Sonis is widely recognized for his studies on the molecular and cellular pathogensis of mucositis, which have resulted in identifying a number of promising pharmaceutical targets to alleviate this universal and incapacitating side of effects of cancer treatment.

He has served as chief medical officer of Biomodels since it was founded in 1997, and holds appointments with the Harvard School of Dental Medicine, the Dana-Farber Cancer Institute, and Brigham and Women's Hospital.

He is the author of more than 100 original publications, 40 reviews and chapters, and seven books. Dr. Sonis serves on a number of editorial boards, and is a founding member of the International Society of Oral Oncology.

About Biomodels

Biomodels (www.biomodels.com), a preclinical contract research organization founded in 1997, has developed and conducted preclinical studies for biotechnology and pharmaceutical companies, particularly in the areas of cancer, cancer supportive care, radiation, therapy, and inflammatory diseases.

The company specializes in (non-GLP) predictive studies that evaluate efficacy and define mechanism of action, enabling clients to expedite the drug discovery process. Biomodels' preclinical studies anticipate clinical objectives and enable organizations to rapidly achieve preclinical milestones.

Photo available upon request.


'/>"/>
SOURCE Biomodels LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Vixiar Medical announced today ... manufacturing functions to The LaunchPort™ Accelerator at the City Garage in Port Covington. ... manufacturing and business services to its Residents. , Vixiar Medical recently closed ...
(Date:9/21/2017)... MA (PRWEB) , ... September 21, 2017 , ... ... proprietary clinical client portal. Each relaunch of the portal includes new features that ... and medical device companies seek to remain at the forefront of medical advancements, ...
(Date:9/21/2017)... GREENVILLE, S.C. (PRWEB) , ... September 21, 2017 ... ... River turned bright neon green this month, the response was swift and efficient ... Group ( RRWQG ). RRWQG is made up of more than 50 stakeholders, ...
(Date:9/20/2017)... ... 2017 , ... The award-winning producers behind the American Farmer ... innovations aimed at helping farmers solve the problem of nitrogen loss. The upcoming ... 8:30aET on RFD-TV. Check your local listings for more info. , As ...
Breaking Biology Technology:
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... 29, 2017  higi, the health IT company that ... North America , today announced a Series B ... of EveryMove. The new investment and acquisition accelerates higi,s ... to transform population health activities through the collection and ... higi collects and secures data today on behalf ...
Breaking Biology News(10 mins):